Cline Scientific extends collaboration agreement with AstraZeneca
As previously communicated, Cline Scientific AB is taking part in a collaboration with AstraZeneca to utilize Cline’s gradient technology as part of the multi-country European MSCA-ITN network, V.A Cure project. The parties have now agreed to continue this collaboration through 2022.The collaboration began in January 2021 and has been focused on using Cline’s gradient surface technology and methodology to develop protocols for differentiation of induced pluripotent stem (iPS) cells into cell types relevant for the repair and treatment of vascular anomalies. Creating such cell types will